Author

M. J. Borad

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

B. M. Nagalo· 2 shared A. Basnakian· 1 shared A. M. Abdelrahman· 1 shared A. S. Mansfield· 1 shared A. T. Baker· 1 shared C. A. Amoreo· 1 shared C. C. Simoes· 1 shared C. Cristofoletti· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

B. M. Nagalo

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy

B. M. Nagalo, Y. Zhang, M. A. Taylor, C. C. Simoes, C. Dumbauld, M. N. Gabere, O. Barro, J. C. Chamcheu, S. R. Post, T. J. Kelly, M. J. Borad, M. J. Cannon, A. Basnakian

This study shows that intratumoral MMR vaccine injections inhibit tumor growth and improve survival in mouse cancer models by enhancing cytotoxic T-cell responses.

bioRxiv · Feb 25, 2022Immunology

Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers

M. Arora, J. M. Bogenberger, A. M. Abdelrahman, J. Yonkus, R. Alva-Ruiz, J. L. Leiting, X. Chen, P. L. Serrano Uson, C. R. Dumbauld, A. T. Baker, S. I. Gamb, J. B. Egan, Y. Zhou, B. M. Nagalo, N. Meurice, , M. J. Borad

This study shows that combining gemcitabine/cisplatin with CDK4/6 inhibitors improves efficacy and reduces toxicity in biliary tract cancers through mechanisms involving autophagy and RRM1 reduction.

bioRxiv · Oct 26, 2020Cancer Biology

FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma unveil a necessary role for Erk signaling

G. Cristinziano, M. Porru, D. Lamberti, S. Buglioni, F. Rollo, C. A. Amoreo, I. Manni, D. Giannarelli, C. Cristofoletti, G. Russo, M. J. Borad, G. L. Grazi, M. G. Diodoro, S. Giordano, M. Forcato, , O. Segatto

This paper develops FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma and shows that Erk signaling is essential for tumor growth, with double blockade of FF-Ras-Erk pathways improving therapeutic efficacy.

bioRxiv · May 20, 2020 · PreprintCancer Biology